Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUE NASDAQ:MIRM NASDAQ:RYTM NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$19.38-4.3%$17.76$3.51▼$25.77$1.63B1.621.39 million shs60,697 shsMIRMMirum Pharmaceuticals$103.87-2.2%$94.04$42.89▼$112.00$6.40B0.52844,929 shs68,627 shsRYTMRhythm Pharmaceuticals$89.87+2.8%$87.61$55.31▼$122.20$6.18B1.94790,894 shs102,244 shsTGTXTG Therapeutics$43.46+0.7%$33.23$25.28▼$44.65$6.65B1.682.12 million shs521,103 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+4.49%+7.77%+15.90%+3.53%+392.94%MIRMMirum Pharmaceuticals-0.92%+9.99%+11.52%+5.21%+139.82%RYTMRhythm Pharmaceuticals-7.20%+6.82%+3.55%-15.05%+52.33%TGTXTG Therapeutics+0.65%+27.50%+27.90%+48.04%+28.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$19.38-4.3%$17.76$3.51▼$25.77$1.63B1.621.39 million shs60,697 shsMIRMMirum Pharmaceuticals$103.87-2.2%$94.04$42.89▼$112.00$6.40B0.52844,929 shs68,627 shsRYTMRhythm Pharmaceuticals$89.87+2.8%$87.61$55.31▼$122.20$6.18B1.94790,894 shs102,244 shsTGTXTG Therapeutics$43.46+0.7%$33.23$25.28▼$44.65$6.65B1.682.12 million shs521,103 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics+4.49%+7.77%+15.90%+3.53%+392.94%MIRMMirum Pharmaceuticals-0.92%+9.99%+11.52%+5.21%+139.82%RYTMRhythm Pharmaceuticals-7.20%+6.82%+3.55%-15.05%+52.33%TGTXTG Therapeutics+0.65%+27.50%+27.90%+48.04%+28.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.67Moderate Buy$32.5067.71% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$136.4231.34% UpsideRYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.8146.68% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5020.81% UpsideCurrent Analyst Ratings BreakdownLatest GLUE, TGTX, MIRM, and RYTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026GLUEMonte Rosa Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$30.00 ➝ $31.005/7/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)5/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$128.00 ➝ $142.005/7/2026MIRMMirum Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$125.00 ➝ $145.005/7/2026MIRMMirum Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$165.005/7/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$185.005/7/2026MIRMMirum Pharmaceuticals EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$138.005/7/2026MIRMMirum Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$136.005/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/7/2026MIRMMirum Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $129.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$123.67M13.24N/AN/A$3.58 per share5.41MIRMMirum Pharmaceuticals$521.31M12.15$0.05 per share2,102.04$6.12 per share16.97RYTMRhythm Pharmaceuticals$189.76M32.45N/AN/A$2.08 per share43.20TGTXTG Therapeutics$616.29M10.79$2.84 per share15.30$4.08 per share10.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$38.63M-$1.48N/AN/AN/A-302.69%-40.99%-25.94%N/AMIRMMirum Pharmaceuticals-$23.36M-$13.61N/A577.03N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%N/ATGTXTG Therapeutics$447.18M$2.8615.2015.63N/A65.95%88.73%43.44%N/ALatest GLUE, TGTX, MIRM, and RYTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3882-$0.45-$0.0618-$0.45$10.95 million$4.21 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 million2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 million2/25/2026Q4 2025MIRMMirum Pharmaceuticals$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A9.549.54MIRMMirum Pharmaceuticals1.282.091.99RYTMRhythm PharmaceuticalsN/A4.173.89TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%MIRMMirum PharmaceuticalsN/ARYTMRhythm PharmaceuticalsN/ATGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.40%MIRMMirum Pharmaceuticals22.87%RYTMRhythm Pharmaceuticals5.90%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9084.48 million79.07 millionOptionableMIRMMirum Pharmaceuticals14060.98 million47.04 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableGLUE, TGTX, MIRM, and RYTM HeadlinesRecent News About These CompaniesHistoric Signal Says This Biotech OutperformsMay 11 at 2:00 PM | schaeffersresearch.comWhy TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI StrengthMay 11 at 11:00 AM | finance.yahoo.comAssessing TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumMay 10 at 1:13 AM | finance.yahoo.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comTGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewMay 7, 2026 | zacks.comTG Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTG Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | seattlepi.comSTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | markets.businessinsider.comTG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings missMay 6, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comTG Therapeutics (TGTX) Q1 Earnings Lag EstimatesMay 6, 2026 | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTXMay 6, 2026 | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | globenewswire.comTG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business UpdateApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTXApril 30, 2026 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by AnalystsApril 30, 2026 | marketbeat.comFortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings GrowthApril 28, 2026 | zacks.comTG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comTG Therapeutics (TGTX) to Release Quarterly Earnings on MondayApril 27, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUE, TGTX, MIRM, and RYTM Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$19.38 -0.88 (-4.35%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$103.87 -2.30 (-2.17%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$89.86 +2.48 (+2.83%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.TG Therapeutics NASDAQ:TGTX$43.46 +0.32 (+0.73%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
